Table 2.

Clinical outcomes of women and men stratified by abciximab administration strategy

Variable	Early abciximab	Late abciximab	OR (95 % CI)	p value	Adjusted OR (95 % CI)	p value
Women	n = 186	n = 86
30 day
Death	4.8 %	14.0 %	0.31 (0.13–0.78)	0.023	0.26 (0.10–0.69)	0.007
Death + nonfatal reinfarction	6.5 %	16.3 %	0.36 (0.16–0.80)	0.013	0.29 (0.12–0.69)	0.005
Death + nonfatal reinfarction + urgent revascularization	7.5 %	17.4 %	0.39 (0.18–0.84)	0.016	0.32 (0.14–0.74)	0.007
Major bleeding requiring transfusion	5.4 %	2.3 %	2.39 (0.51–11.13)	0.27	2.22 (0.47–10.57)	0.32
Intracranial haemorrhage	0 %	0 %	–	–	–	–
Puncture site haematoma	12.9 %	9.3 %	1.44 (0.62–3.36)	0.39	1.21 (0.51–2.88)	0.67
All bleeding	16.7 %	11.6 %	1.52 (0.71–3.26)	0.28	1.30 (0.60–2.85)	0.51
1 year
Death	7.5 %	17.4 %	0.39 (0.18–0.84)	0.016	0.37 (0.16–0.84)	0.017
Men	n = 541	n = 273
30 day
Death	3.7 %	5.5 %	0.66 (0.33–1.31)	0.24	0.69 (0.35–1.39)	0.27
Death + nonfatal reinfarction	4.6 %	7.0 %	0.65 (0.35–1.20)	0.17	0.68 (0.37–1.28)	0.23
Death + nonfatal reinfarction + urgent revascularization	5.0 %	8.1 %	0.60 (0.34–1.07)	0.09	0.64 (0.36–1.17)	0.15
Major bleeding requiring transfusion	1.3 %	1.1 %	1.18 (0.30–4.60)	0.81	1.40 (0.35–5.64)	0.64
Intracranial haemorrhage	0 %	0 %	–	–	–	–
Puncture site haematoma	6.7 %	7.3 %	0.90 (0.51–1.59)	0.72	0.94 (0.53–1.68)	0.83
All bleeding	7.6 %	8.1 %	0.94 (0.55–1.61)	0.81	0.98 (0.57–1.71)	0.95
1 year
Death	5.2 %	8.1 %	0.62 (0.35–1.11)	0.11	0.68 (0.38–1.22)	0.19

Values are presented as percentages and unadjusted and adjusted for propensity score odds ratios (OR) with 95 % confidence intervals (CI)